Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation

Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation

Objectives: To test the potential of fimepinostat (CUDC-907), a dual inhibitor of histone deacetylases (HDAC) and phosphatidylinositol-3-kinases (PI3K), to reverse human immunodeficiency virus type 1 (HIV-1) latency in infected cell lines and in CD4+ T cells from HIV-1-infected donors on long-term c...

Full description

Bibliographic Details
Main Authors: Jesper D. Gunst, Kathrine Kjær, Rikke Olesen, Thomas A. Rasmussen, Lars Østergaard, Paul W. Denton, Ole S. Søgaard, Martin Tolstrup
Format: Article
Language:English
Published: Elsevier 2019-07-01
Series:Journal of Virus Eradication
Subjects:
HIV
latency-reversal agent
T cell activation
HDACi
PI3Ki
fimepinostat
Online Access:http://www.sciencedirect.com/science/article/pii/S205566402030042X

Similar Items

Similar Items